Patent Assignment
Reel/Frame 067348/0160
Security Interest
Recorded: 2024-05-08
Pages: 14
Assignors
COHERUS BIOSCIENCES, INC.
Executed: 2024-05-08
COHERUS INTERMEDIATE CORP.
Executed: 2024-05-08
INTEKRIN THERAPEUTICS INC.
Executed: 2024-05-08
SURFACE ONCOLOGY, LLC
Executed: 2024-05-08
COHERUS ONCOLOGY SUPPORTIVE CARE LLC
Executed: 2024-05-08
Assignee
ANKURA TRUST COMPANY, LLC
140 SHERMAN STREET, 4TH FLOOR, FAIRFIELD, CONNECTICUT, 06824
Covered Properties
(98)
Etanercept Formulations Stabilized with Metal Ions
Etanercept Formulations Stabilized with Xylitol
Solid Pharmaceutical Compositions of Ppary Modulator
Ppar Gamma Agonists for Treatment of Multiple Sclerosis
Perfusion Method for Manufacturing Etanercept
Etanercept Formulations Exhibiting Marked Reduction in Sub-Visible Particles
Stable Aqueous Formulations of Etanercept
Method of Manufacturing a Protein by Perfusion in Media with a Low Amino Acid Concentration
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Ppar Gamma Agonists for Treatment of Multiple Sclerosis
Correctly Folded Etanercept Composition
Methods for Making Recombinant Proteins
Patent:
10,435,464 →
Application:
14/845,440 →
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Etanercept Formulations Stabilized with Combinations of Sugars and Polyols
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Etanercept Formulations Stabilized with Xylitol
High Concentration Formulations of Adalimumab
Patent:
11,229,702 →
Application:
15/337,519 →
Stable Adalimumab Compositions and Methods of Their Use
Patent:
11,583,584 →
Application:
15/337,845 →
Stable Aqueous Formulations of Adalimumab
Ppar Gamma Agonists for Treatment of Multiple Sclerosis
Method of Filling a Container with No Headspace
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Correctly Folded Etanercept in High Purity and Excellent Yield
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Syringe Containing Stable Aqueous Formulations of Adalimumab
Methods of Manufacturing Stable Aqueous Formulations of Adalimumab
Etanercept Formulations Stabilized with Metal Ions
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Antibodies That Bind CD39 and Uses Thereof
Antibody Molecules to CD73 and Uses Thereof
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Method of Manufacturing a Protein by Perfusion in Media with a Low Amino Acid Concentration
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Stable Aqueous Formulations of Adalimumab
Etanercept Formulations Stabilized with Xylitol
Stable Aqueous Formulations of Aflibercept
Antibodies That Bind CD39 and Uses Thereof
Etanercept Formulations Stabilized with Amino Acids
Anti-Il-27 Antibodies and Uses Thereof
Stable Aqueous Etanercept Composition
Method of Reducing Formation of Etanercept Aggregates or Fragments
Stable Aqueous Etanercept Composition
Method of Reducing Formation of Etanercept Aggregates or Fragments
Correctly Folded Etanercept in High Purity and Excellent Yield
Correctly Folded Etanercept in High Purity and Excellent Yield
Correctly Folded Etanercept in High Purity and Excellent Yield
Correctly Folded Etanercept in High Purity and Excellent Yield
Etanercept Formulations Stabilized with Sodium Chloride
PPARy AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
Anti-CD112R Compositions and Methods
Methods for Making Recombinant Proteins
Patent:
11,396,540 →
Application:
16/564,642 →
Stable Aqueous Formulations of Aflibercept
Methods for the Treatment of Nonalcoholic Fatty Liver Disease and/or Lipodystrophy
Methods for the Treatment of Nonalcoholic Fatty Liver Disease and/or Lipodystrophy
Anti-CD39 Antibody Compositions and Methods
Antibody Molecules to CD73 and Uses Thereof
Application:
17/059,056 →
Publication:
US 2021/0214459
Anti-CD112R Compositions and Methods
Method of Filling a Container with No Headspace
Anti-Il-27 Antibodies and Uses Thereof
Compositions and Methods to Treat Non-Alcoholic Fatty Liver Diseases (Nafld)
Application:
17/419,559 →
Publication:
US 2022/0143003
Anti-CD112R Compositions and Methods
Compositions and Methods to Treat Non-Alcoholic Fatty Liver Diseases (Nafld)
Application:
17/600,168 →
Publication:
US 2022/0193102
Compositions and Methods to Treat Non-Alcoholic Fatty Liver Diseases (Nafld)
Application:
17/600,172 →
Publication:
US 2022/0193065
Compositions and Methods to Treat Non-Alcoholic Fatty Liver Diseases (Nafld)
Application:
17/600,178 →
Publication:
US 2022/0288053
Compositions and Methods to Treat Non-Alcoholic Fatty Liver Diseases (Nafld)
Application:
17/600,182 →
Publication:
US 2022/0288054
Compositions and Methods to Treat Non-Alcoholic Fatty Liver Diseases (Nafld)
Application:
17/600,194 →
Publication:
US 2022/0175758
Compositions and Methods to Treat Cancer
Application:
17/613,012 →
Publication:
US 2022/0202804
Antibody Molecules to CD73 and Uses Thereof
Application:
17/695,267 →
Publication:
US 2023/0039109
Anti-Il-27 Antibodies and Uses Thereof
Application:
17/714,942 →
Publication:
US 2023/0042258
Anti-Il-27 Antibodies and Uses Thereof
Control Mechanism for Priming an Injection Device
Application:
17/765,294 →
Publication:
US 2022/0339360
Compositions and Methods to Treat Non-Alcoholic Fatty Liver Diseases (Nafld)
Application:
17/768,538 →
Publication:
US 2024/0066020
Methods of Treating Cancer with an Anti-CD39 Antibody and Pembrolizumab
Application:
17/830,817 →
Publication:
US 2023/0036592
Use of Anti-Il-27 Antibodies
Application:
18/201,620 →
Publication:
US 2024/0026001
Use of Anti-Il-27 Antibodies
Application:
18/201,626 →
Publication:
US 2024/0025987
Related Assignments
(14)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jan 8, 2013
From: MANNING, MARK; MURPHY, BRIAN
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 029590/0397 →
Assignment of Assignor's Interest
Jan 8, 2013
From: MANNING, MARK; MURPHY, BRIAN
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 029590/0561 →
Assignment of Assignor's Interest
Feb 6, 2014
From: WEINSTEIN, DAVID
To: INTEKRIN THERAPEUTICS, INC.
Reel/Frame 032166/0840 →
Assignment of Assignor's Interest
Mar 4, 2015
From: MANNING, MARK; MURPHY, BRIAN; FARRAR, DOUGLAS; HERMAN, ALAN
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 035083/0126 →
Assignment of Assignor's Interest
May 8, 2015
From: WEINSTEIN, DAVID
To: INTEKRIN THERAPEUTICS, INC.
Reel/Frame 035626/0182 →
Assignment of Assignor's Interest
Sep 24, 2015
From: PUCHACZ, ELA; GROVE, JAMES RUSSELL
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 036643/0917 →
Assignment of Assignor's Interest
Jan 7, 2016
From: MANNING, MARK; PAYNE, ROBERT
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 037428/0498 →
Assignment of Assignor's Interest
Jan 13, 2016
From: MANNING, MARK; MURPHY, BRIAN
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 037472/0665 →
Security Interest
Jan 7, 2019
From: COHERUS BIOSCIENCES, INC.; COHERUS INTERMEDIATE CORP.; INTEKRIN THERAPEUTICS INC.
To: HCR COLLATERAL MANAGEMENT, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 048021/0975 →
Assignment of Assignor's Interest
Sep 24, 2020
From: PUCHACZ, ELZBIETA WIKTORIA
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 053875/0711 →
Release of Notice of Grant of Security Interest in Patents at Reel/Frame No. 048021/0975
Jan 11, 2022
From: HCR COLLATERAL MANAGEMENT, LLC
To: COHERUS BIOSCIENCES, INC.; COHERUS INTERMEDIATE CORP.; INTEKRIN THERAPEUTICS INC.
Reel/Frame 058692/0665 →
Security Interest
Mar 18, 2022
From: COHERUS BIOSCIENCES, INC.; COHERUS INTERMEDIATE CORP.; INTEKRIN THERAPEUTICS INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 059436/0055 →
Termination and Release of Security Interest in Intellectual Property at Reel/Frame No. 59436/0055
May 9, 2024
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: COHERUS BIOSCIENCES, INC.; COHERUS INTERMEDIATE CORP.; INTEKRIN THERAPEUTICS INC.
Reel/Frame 067378/0256 →
Assignment of Assignor's Interest
Oct 31, 2024
From: COHERUS BIOSCIENCES, INC.
To: HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD.
Reel/Frame 069084/0884 →